According to a release issued by Ranbaxy to the BSE today, RPCI has already received approvals to sell eight products in Canada in the anti-infective, diabetes and cardiovascular segment including Carvedilol, Ciprofloxacin, Citalopram, Domperidone, Lovastatin, Atenolol, Metformin and Zepiclone.
Malvinder M Singh, president (pharmaceuticals) and executive director of Ranbaxy, said: "Our R&D efficiencies and globally integrated systems enable us to develop pharmaceuticals and bring them to market quickly and efficiently. As a result of our efficiency as well as our highly competitive manufacturing costs and lower innovation expenses, the Canadian healthcare system, government and consumers will benefit from more competitive prices of medicines."
